Design Therapeutics

DSGN

ATLANTA, GA – – (ACCESSWIRE – December 29, 2022) – – Holzer & Holzer, LLC is investigating whether Design Therapeutics, Inc. (“Design Therapeutics” or the “Company”) (NASDAQ: DSGN) complied with federal securities laws. On December 7, 2022, Design Therapeutics announced initial results from the Company’s Phase 1 clinical trial in patients with Friedreich ataxia. As part of the initial results, the Company disclosed that “16 (73%) patients on DT-216 and eight (73%) patients on placebo reported at least one treatment-emergent adverse event.” Following this disclosure, the Company’s stock price dropped.

If you purchased Design Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website https://holzerlaw.com/case/design-therapeutics/  to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

View Representation Agreement

Submit Your Information

Name(Required)

First Last

Email(Required)

Phone(Required)

Address

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Shares Purchased(Required)

Number of Shares Acquired

Acquisition Price Per Share

Shares Sold

Number of Shares Sold

Selling Price Per Share

By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.

I agree

Signed pursuant to the Uniform Electronic Transactions act as adopted by the various states and territories of the United States.

CAPTCHA